Listing of Claims:

1. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier substance and a compound of the formula (I) or (Ia), and/or a pharmaceutically acceptable acid addition salt thereof,



(I)



(Ia)

in which the substituents have the following significance:

R_1: C_1-C_6-alkyl; C_2-C_6-alkenyl; C_2-C_6-alkinyl; C_3-C_{16}-(cyclical saturated group)alkyl, where alkyl is C_1-C_6; C_4-C_{16}-(cyclical saturated group)alkenyl, where alkenyl is C_2-C_6; C_4-C_{16}-(cyclical saturated group)alkinyl, where alkinyl is C_2-C_6; C_7-C_{16}-arylalkyl where aryl is C_6-C_{10}-aryl and alkyl is C_1-C_6-alkyl; C_8-C_{16}-arylalkenyl, where aryl is C_6-C_{10}-aryl and alkenyl is C_2-C_6-alkenyl; C_8-C_{16}-arylalkinyl, where aryl is C_6-C_{10}-aryl and alkinyl is C_2-C_6-alkinyl;

R_2: C_4-C_6-alkyl; C_2-C_6-alkinyl; C_3-C_{16}-(cyclical saturated group)alkyl, where alkyl is C_1-C_6; C_4-C_{16}-(cyclical saturated group)alkenyl, where alkenyl is C_2-C_6; C_4-C_{16}-(cyclical saturated group)alkinyl, where alkinyl is C_2-C_6; C_8, C_9, C_{10}, C_{11}, C_{12}, C_{13}, C_{14}, C_{15}, or C_{16}-arylalkyl, where

aryl is C_6-C_{10}-aryl and alkyl is C_1-C_6-alkyl; C_8, C_{10}, C_{11}, C_{12}, C_{13}, C_{14}, C_{15} or C_{16}-arylalkenyl, where aryl is C_6-C_{10}-aryl and alkenyl is C_2-C_6-alkenyl; C_8-C_{16}-arylalkinyl, where aryl is C_6-C_{10}-aryl and alkinyl is C_2-C_6-aklinyl; C_3-C_6-alkinoyl; and C_9-C_{16}-arylalkinoyl, where aryl is C_6-C_{10}-aryl and alkinoyl is C_3-C_6-alkinoyl;

R_3: hydrogen, C_1-C_6-alkyl; C_2-C_6-alkenyl; C_7-C_{16}-arylalkyl, where aryl is C_6-C_{10}-aryl and alkyl is C_1-C_6-alkyl; C_8-C_{16}-arylalkenyl, where aryl is C_6-C_{10}-aryl and alkenyl is C_2-C_6-alkenyl; alkoxyalkyl, where alkoxy is C_1-C_6-alkoxy and alkyl is C_1-C_6-alkyl; $CO_2(C_1$-C_6-alkyl); CO_2H; CH_2OH;

R_4: hydrogen; hydroxy; C_1-C_6-alkyloxy; C_2-C_{10}-alkyloxyalkoxy, where alkyloxy is C_1-C_4 alkyloxy and alkoxy is C_1-C_6-alkyloxy; C_2-C_6-alkenyloxy; C_2-C_6-alkinyloxy; C_3-C_{16}-(cyclical saturated group)alkyloxy, where alkyl is C_1-C_6 alkyl; C_4-C_{16}-(cyclical saturated group)alkenyloxy, where alkenyl is C_2-C_6 alkenyl; C_4-C_{16}-(cyclical saturated group)alkinyloxy where alkinyl is C_2-C_6 alkinyl; C_7-C_{16}-arylalkyloxy, where aryl is C_6-C_{10}-aryl and alkyl is C_1-C_6-alkyl; C_8-C_{16}-arylalkenyloxy, where aryl is C_6-C_{10}-aryl and alkenyl is C_2-C_6-alkenyl; C_8-C_{16}-arylalkinyloxy, where aryl is C_6-C_{10}-aryl and alkinyl is C_2-C_6-alkinyl; C_1-C_6-alkanoyloxy; C_3-C_6-alkenoyloxy; C_3-C_6-alkinoyloxy; C_7-C_{16}-arylalkanoyloxy, where aryl is C_6-C_{10}-aryl and alkanoyloxy is C_2-C_6-alkanoyloxy; C_9-C_{16}-arylalkenoyloxy, where aryl is C_6-C_{10}-aryl and alkenoyloxy is C_3-C_6-alkenoyloxy; C_9-C_{16}-arylalkinoyloxy, where aryl is C_6-C_{10}-aryl and alkinoyloxy is C_3-C_6-alkinoyloxy;

R_5: hydrogen; hydroxy; C_1-C_6-alkyloxy; C_2-C_{10}-alkyloxyalkoxy, where alkyloxy is C_1-C_4 alkyloxy and alkoxy is C_1-C_6-alkyloxy; C_2-C_6-alkenyloxy; C_2-C_6-alkinyloxy; C_3-C_{16}-(cyclical saturated group)alkyloxy, where alkyl is C_1-C_6 alkyl; C_4-C_{16}-(cyclical saturated group)alkenyloxy, where alkenyl is C_2-C_6 alkenyl; C_4-C_{16}-(cyclical saturated group)alkinyloxy, where alkinyl is C_2-C_6 alkinyl; C_7-C_{16}-arylalkyloxy, where aryl is C_6-C_{10}-aryl and alkyl is C_1-C_6-alkyl; C_8-C_{16}-arylalkenyloxy, where aryl is C_6-C_{10}-aryl and alkenyl is C_2-C_6-alkenyl; C_8-C_{16}-arylalkinyloxy, where aryl is C_6-C_{10}-aryl and alkinyl is C_2-C_6-alkinyl; C_2-C_6-alkanoyloxy; C_7-C_{16}-arylalkanoyloxy, where aryl is C_6-C_{10}-aryl and alkanoyloxy is C_2-C_6-alkanoyloxy;

X is oxygen;

wherein a single or double bond can be present between the carbon atoms of numbers 7 and 8,

wherein alkyl, alkenyl and alkinyl can each be branched or unbranched, aryl can be unsubstituted or mono-, di- or trisubstituted, independently in each case, with hydroxy, halogen, nitro, cyano, thiocyanato, trifluoromethyl, C_1-C_3-alkyl, C_1-C_3-alkoxy, CO_2H, $CONH_2$, $CO_2(C_1$-C_3-alkyl), $CONH(C_1$-C_3-alkyl), $CON(C_1$-C_3-alkyl)$_2$, $CO(C_1$-C_3-alkyl); amino; (C_1-C_3-monoalkyl)amino, (C_1-C_3-dialkyl)amino; C_5-C_6-cycloalkylamino, (C_1-C_3-alkanoyl)amido, SH, SO_3H, $SO_3(C_1$-C_3-alkyl), $SO_2(C_1$-C_3-alkyl), $SO(C_1$-C_3-alkyl), C_1-C_3-alkylthio or C_1-C_3-alkanoylthio,

wherein -(cyclical saturated group) is either preferably C_3-C_{10}-cycloalkyl or a heterocyclic group with 2 to 9 carbon atoms, containing further one or more heteroatoms,

with the exception of compounds where R_1 is methyl, R_2 is C_4-C_6-alkyl, R_3 is hydrogen or methyl, R_4 is hydroxy or methoxy and R_5 is hydroxy, methoxy or an oxygen atom bound to the carbon atom in the 5th position,

with the further exception of compounds where R_1 is cyclopropylmethyl and XR_2 is benzyloxy, when R_4 is hydrogen or benzyloxy and R_5 is an oxygen atom bound to the carbon atom in the 5th position; and

with the further exception of compounds where R_1 is cyclopropylmethyl and XR_2 is benzyloxy, when R_4 is hydrogen, hydroxy or benzyloxy and R_5 is hydroxy or methoxy.

2. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier substance and a compound of the formula (IA) or (IAa), and/or a pharmaceutically acceptable acid addition salt thereof,



(IA)



(IAa)

where the substituents have the following significance:

R_1: C_1-C_6-alkyl; C_2-C_6-alkenyl; C_2-C_6-alkinyl; C_3-C_{16}-(cyclical saturated group)alkyl, where alkyl is C_1-C_6; C_4-C_{16}-(cyclical saturated group)alkenyl, where alkenyl is C_2-C_6; C_4-C_{16}-(cyclical saturated group)alkinyl, where alkinyl is C_2-C_6; C_7-C_{16}-arylalkyl, where aryl is C_6-C_{10}-aryl and alkyl is C_1-C_6-alkyl; C_8-C_{16}-arylalkenyl, where aryl is C_6-C_{10}-aryl and alkenyl is C_2-C_6-alkenyl; C_8-C_{16}-arylalkinyl, where aryl is C_6-C_{10}-aryl and alkinyl is C_2-C_8-alkinyl;

wherein the two substituents R_1 can be the same or different;

R_2: C_2-alkyl, C_3-alkyl, C_4-alkyl, C_5-alkyl or C_6-alkyl; C_2-C_6-alkenyl; C_2-C_6-alkinyl; C_3-C_{16}-(cyclical saturated group)alkyl, where alkyl is C_1-C_6; C_4-C_{16}-(cyclical saturated group)alkenyl, where alkenyl is C_2-C_6; C_4-C_{16}-(cyclical saturated group)alkinyl, where alkinyl is C_2-C_6; C_{78}-C_{16}-arylalkyl, where aryl is C_6-C_{10}-aryl and alkyl is C_1-C_6-alkyl; C_8-C_{16}-arylalkenyl, where aryl is C_6-C_{10}-aryl and alkenyl is C_2-C_6-alkenyl; C_8-C_{16}-arylalkinyl, where aryl is C_6-C_{10}-aryl and alkinyl is C_2-C_6-alkinyl; C_3-C_6-alkenoyl; C_3-C_6-alkinoyl; C_9-C_{16}-arylalkenoyl, where aryl is C_6-C_{10}-aryl and alkenoyl is C_3-C_6-alkenoyl; C_9-C_{16}-arylalkinoyl, where aryl is C_6-C_{10}-aryl and alkinoyl is C_3-C_6-alkinoyl;

R_3: hydrogen, C_1-C_6-alkyl; C_2-C_6-alkenyl; C_7-C_{16}-arylalkyl, where aryl is C_6-C_{10}-aryl and alkyl is C_1-C_6-alkyl; C_8-C_{16}-arylalkenyl, where aryl is C_6-C_{10}-aryl and alkenyl is C_2-C_6-alkenyl; alkoxyalkyl, where alkoxy is C_1-C_6-alkoxy and alkyl is C_1-C_6-alkyl; CO_2(C_1-C_6-alkyl); CO_2H; CH_2OH;

R_4: hydrogen; hydroxy; C_1-C_6-alkyloxy; C_2-C_{10}-alkyloxyalkoxy, where alkyloxy is C_1-C_4 alkyloxyl and alkoxy is C_1-C_6-alkyloxy; C_2-C_6-alkenyloxy; C_2-C_6-alkinyloxy; C_3-C_{16}-(cyclical saturated group)alkyloxy, where alkyl is C_1-C_6 alkyl; C_4-C_{16}-(cyclical saturated group)alkenyloxy, where alkenyl is C_2-C_6 alkenyl; C_4-C_{16}-(cyclical saturated group)alkinyloxy where alkinyl is C_2-C_6 alkinyl; C_7-C_{16}-arylalkyloxy, where aryl is C_6-C_{10}-aryl and alkyl is C_1-C_6-alkyl; C_8-C_{16}-arylalkenyloxy, where aryl is C_6-C_{10}-aryl and alkenyl is C_2-C_6-alkenyl; C_8-C_{16}-arylalkinyloxy, where aryl is C_6-C_{10}-aryl and alkinyl is C_2-C_6-alkinyl; C_2-C_6-alkanoyloxy; C_3-C_6-alkenoyloxy; C_3-C_6-alkinoyloxy; C_8-C_{16}-arylalkanoyloxy, where aryl is C_6-C_{10}-aryl and alkanoyloxy is C_2-C_6-alkanoyloxy; C_9-C_{16}-arylalkenoyloxy, where aryl is C_6-C_{10}-aryl and alkenoyloxy is C_3-C_6-alkenoyloxy; C_9-C_{16}-arylalkinoyloxy, where aryl is C_6-C_{10}-aryl and alkinoyloxy is C_3-C_6-alkinoyloxy;

R_5: hydrogen; hydroxy; C_1-C_6-alkyloxy; C_2-C_{10}-alkyloxyalkoxy, where alkyloxy is C_1-C_4 alkyloxy and alkoxy is C_1-C_6-alkyloxy; C_2-C_6-alkenyloxy; C_2-C_6-alkinyloxy; C_3-C_{16}-(cyclical saturated group)alkyloxy, where alkyl is C_1-C_6 alkyl; C_4-C_{16}-(cyclical saturated group)alkenyloxy, where alkenyl is C_2-C_6 alkenyl; C_4-C_{16}-(cyclical saturated group)alkinyloxy, where alkinyl is C_2-C_6 alkinyl; C_7-C_{16}-arylalkyloxy, where aryl is C_6-C_{10}-aryl and alkyl is C_1-C_6-alkyl; C_8-C_{16}-arylalkenyloxy, where aryl is C_6-C_{10}-aryl and alkenyl is C_2-C_6-alkenyl; C_8-C_{16}-arylalkinyloxy, where aryl is C_6-C_{10}-aryl and alkinyl is C_2-C_6-alkinyl; C_2-C_6-alkanoyloxy; C_7-C_{16}-arylalkanoyloxy, where aryl is C_6-C_{10}-aryl and alkanoyloxy is C_2-C_6-alkanoyloxy;

X is oxygen;

Y^- is I^-, Br^-, Cl^-, OH^- or another pharmacologically acceptable counterion;

wherein a single or double bond can be present between the carbon atoms of numbers 7 and 8,

wherein alkyl, alkenyl and alkinyl can each be branched or unbranched, aryl can be unsubstituted or mono-, di- or trisubstituted, independently in each case, with hydroxy, halogen, nitro, cyano, thiocyanato, trifluoromethyl, C_1-C_3-alkyl, C_1-C_3-alkoxy, CO_2H, $CONH_2$, $CO_2(C_1$-C_3-alkyl), $CONH(C_1$-C_3-alkyl), $CON(C_1$-C_3-alkyl)$_2$, $CO(C_1$-C_3-alkyl); amino; (C_1-C_3-monoalkyl)amino, (C_1-C_3-dialkyl)amino; C_5-C_6-cycloalkylamino, (C_1-C_3-alkanoyl)amido, SH, SO_3H, $SO_3(C_1$-C_3-alkyl), $SO_2(C_1$-C_3-alkyl), $SO(C_1$-C_3-alkyl), C_1-C_3-alkylthio or C_1-C_3-alkanoylthio, wherein -(cyclical saturated group) is either preferably C_3-C_{10}-cycloalkyl or a heterocyclical group with 2 to 9 carbon atoms, containing furthermore one or more heteroatoms.

3. (Previously Presented) A composition of claim 1 or 2, wherein for the compound of formula (I) or (IA), R_1 is C_1-C_6-alkyl; C_2-C_6-alkenyl; C_4-C_{16}-cycloalkylalkyl, where cycloalkyl is C_3-C_{10} cycloalkyl and alkyl is C_1-C_6 alkyl; C_7-C_{16}-arylalkyl, where aryl is C_6-C_{10}-aryl and alkyl is C_1-C_6-alkyl; R_2 is C_8-C_{16}-arylalkyl, where aryl is C_6-C_{10}-aryl and alkyl is C_1-C_6-alkyl; C_8-arylalkenyl or C_{10}-C_{16}-arylalkenyl, where aryl is C_6-C_{10}-aryl and alkenyl is C_2-C_6-alkenyl; R_3 is hydrogen or methyl; R_4 is hydroxy, methoxy or acetoxy.

4. (Previously Presented) A composition of claim 2, wherein for the compound of formula (IA), R_1 is C_1-C_6-alkyl; C_2-C_6-alkenyl; C_4-C_{16}-cycloalkylalkyl, where cycloalkyl is C_3-C_{10} cycloalkyl and alkyl is C_1-C_6 alkyl; C_7-C_{16}-arylalkyl, where aryl is C_6-C_{10}-aryl and alkyl is C_1-C_6-alkyl; R_2 is C_2-C_6-alkyl or C_2-C_6-alkenyl, R_3 is hydrogen or methyl; R_4 is hydroxy, methoxy or acetoxy.

5. (Previously Presented) A composition of claim 1 or 2, wherein the compound is selected from:

17-allyl-4,5α-epoxy-3-methoxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5α-epoxy-3-hydroxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5α-epoxy-3-methoxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5α-epoxy-3-hydroxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5α-epoxy-3-methoxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5α-epoxy-3-hydroxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5α-epoxy-3-methoxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5α-epoxy-3-hydroxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5α-epoxy-3-methoxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5α-epoxy-3-methoxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 4,5α-epoxy-3-methoxy-5β,17-dimethyl-14β-[(3-phenylpropyl)oxy)morphinan-6-one, 4,5α-epoxy-3-hydroxy-5β,17-dimethyl-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 17-propyl-4,5α-epoxy-3-methoxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-propyl-4,5α-epoxy-3-hydroxy-14β-(3-

phenylpropyloxy)morphinan-6-one, 17-propyl-4,5α-epoxy-3-methoxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-propyl-4,5α-epoxy-3-hydroxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5α-epoxy-3-methoxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5α-epoxy-3-hydroxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5α-epoxy-3-methoxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5α-epoxy-3-hydroxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5α-epoxy-3-methoxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5α-epoxy-3-hydroxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5α-epoxy-3-methoxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5α-epoxy-3-hydroxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5α-epoxy-3-methoxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5α-epoxy-3-hydroxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5α-epoxy-3-methoxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5α-epoxy-3-hydroxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-[(2-methylbenzyl)oxy]morphinan-6-one, 14β-butoxy-17-cyclopropylmethyl-4,5α-epoxy-3-hydroxymorphinan-6-one, 4,5α-epoxy-5β,17-dimethyl-14β-[(3-phenylpropyl)oxy]-3-[(prop-2-inyl)oxy]morphinan-6-one, 4,5α-epoxy-17-ethyl-3-methoxy-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 4,5α-epoxy-17-ethyl-3-hydroxy-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 4,5α-epoxy-3-hydroxy-14β-[(3-methylbutyl)oxy]-17-propylmorphinan-6-one, 4-hydroxy-3-methoxy-17-methyl-14-[(3-phenylpropyl)oxy]-morphinan-6-one, 3,4-dimethoxy-17-methyl-14-[(3-phenylpropyl)oxy]-morphinan-6-one, 4-hydroxy-3-methoxy-17-methyl-14β-[(2-naphthylmethyl)oxy]morphinan-6-one, 3,4-dimethoxy-17-methyl-

14β-[(2-naphthylmethyl)oxy]morphinan-6-one, 4-hydroxy-3-methoxy-5β,17-dimethyl-14β-[(3-phenylpropyl)oxy]-morphinan-6-one, 3,4-dimethoxy-5β,17-dimethyl-14β-[(3-phenylpropyl)oxy]-morphinan-6-one, 4,5α-epoxy-3-hydroxy-17,17-dimethyl-6-oxo-14β-[(3-phenylpropyl)oxy]morphinanium-iodide, (17S)-4,5α-epoxy-17-ethyl-3-hydroxy-17-methyl-6-oxo-14β-[(3-phenylpropyl)oxy]morphinanium-iodide, (17R)-4,5α-epoxy-3-hydroxy-17-methyl-6-oxo-14β-[(3-phenylpropyl)oxy]-17-[(2(R,S)-tetrahydrofurfuran-2-yl)methyl]morphinanium-iodide, 5β-benzyl-14β-(butyloxy)-4,5-epoxy-3-hydroxy-17,17-dimethyl-6-oxomorphinanium-iodide, (17S)-17-allyl-5β-benzyl-14β-butoxy-4,5α-epoxy-3-hydroxy-17-methyl-6-oxomorphinanium-iodide, 14β-butoxy-4,5α-epoxy-3-hydroxy-17,17-dimethyl-6-oxomorphinanium-iodide, (17R)-17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-17-methyl-6-oxo-14β-[(3-phenylpropyl)oxy]morphinanium-iodide, (17R)-17-cyclopropylmethyl-4,5α-epoxy-3-methoxy-17-methyl-6-oxo-14β-[(3-phenylpropyl)oxy]morphinanium-iodide, (17R)-17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-17-methyl-6-oxo-14β-[(2-phenylbenzyl)oxy]morphinanium-iodide, 4,5α-expoxy-3-methoxy-17-methyl-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 4,5α-expoxy-3-methoxy-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 4,5α-expoxy-3-hydroxy-17-methyl-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 4,5α-expoxy-17-methyl-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 17-(cyclopropylmethyl)-4,5α-epoxy-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 4,5α-epoxy-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 17-(cyclopropylmethyl)-4-hydroxy-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 17-(cyclopropylmethyl)-4-methoxy-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 4-(n-butyloxy)-17-(cyclopropylmethyl)-14β-[(3-phenylpropyl)oxy]morphinan-6-one, and a pharmaceutically acceptable salt thereof.

Claim 6. (Cancelled)

Claim 7. (Cancelled).

8. (Previously Presented) A method of treating pain, comprising the step of administering to a patient in need thereof an effective amount of the composition of claim 1 or 2.

9. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R_5 is OH or alkyloxy.

10. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R_3 is hydrogen, alkyl or aralkyl.

11. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R_4 is OH, alkyloxy, alkenyloxy or alkinyloxy.

12. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, a single bond is present between carbon atom numbers 7 and 8.

13. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R_2 is alkyl or aralkyl.

14. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R_1 is alkyl, (cyclical saturated group)alkyl, aralkyl or alkenyl.

15. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R_1 is C_1-C_6-alkyl; C_2-C_6-alkenyl; C_2-C_6-alkinyl; C_3-C_{16}-(cyclical saturated group)alkyl, where alkyl is C_1-C_6 alkyl; C_4-C_{16}-(cyclical saturated group)alkenyl, where alkenyl is C_2-C_6 alkenyl; C_4-C_{16}-(cyclical saturated group)alkinyl, where alkinyl is C_2-C_6 alkinyl; C_7-C_{16}-arylalkyl, where aryl is C_6-C_{10}-aryl and alkyl is C_1-C_6-alkyl; C_8-C_{16}-arylalkenyl, where aryl is C_6-C_{10}-aryl and alkenyl is C_2-C_6-alkenyl; C_8-C_{16}-arylalkinyl, where aryl is C_6-C_{10}-aryl and alkinyl is C_2-C_6-alkinyl.

16. (Previously Presented) A composition according to claim 10, wherein in the compound, R_3 is hydrogen or alkyl.

17. (Previously Presented) A composition according to claim 13, wherein in the compound, R_2 is aralkyl.

18. (Currently Amended) A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier substance and (ii) a compound and/or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:
14β-[(2-chlorobenzyl)oxy]-17-(cyclopropylmethyl)-4,5α-epoxy-3-hydroxymorphinan-6-one, ~~14β-benzyloxy-17-cyclopropylmethyl-4,5α-epoxy-3-hydroxymorphinan-6-one,~~ 17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-[(3-methylbutyl)oxy]morphinan-6-one, 14β-[(3-

chlorobenzyl)oxy]-4,5α-epoxy-17-methyl-3-[(prop-2-inyl)oxy]morphinan-6-one, 5β-benzyl-14-methoxycodeinone (= 5-benzyl-7,8-didehydro-4,5α-epoxy-3,14β-dimethoxy-17-methyl-morphinan-6-one), 5β-benzyl-4,5α-epoxy-3,14β-dimethoxy-17-methylmorphinan-6-one, 5β-benzyl-4,5α-epoxy-3-hydoxy-14β-methoxy-17-methylmorphinan-6-one, 14β-benzyloxy-4-hydroxy-3-methoxy-17-methylmorphinan-6-one, 14β-benzyloxy-3,4-dimethoxy-17-methylmorphinan-6-one, 14β-ethoxy-4-hydroxy-3-methoxy-5β,17-dimethylmorphinan-6-one, 14β-ethoxy-3,4-dimethoxy-5β,17-dimethylmorphinan-6-one, 14β-benzyloxy-3,4-dimethoxy-5β,17-dimethylmorphinan-6-one, (17R)-17-allyl-4,5α-epoxy-14β-ethoxy-3-hydroxy-17-methyl-6-oxomorphinanium-iodide, (17R)-17-allyl-4,5α-epoxy 3-hydroxy-14β-methoxy-17-methyl-6-oxomorphinanium-iodide, (17S)-17-allyl-4,5α-epoxy-3-hydroxy-14β-methoxy-17-methyl-6-oxomorphinanium-iodide, 4,5α-epoxy-3-hydroxy-14β-methoxy-17,17-dimethyl-6-oxo-morphinanium-iodide, (17R)-14β-[(4-chlorobenzyl)oxy]-17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-17-methyl-6-oxomorphinanium-iodide and 17(R)-4,5α-epoxy-3-hydroxy-14β-methoxy-17-methyl-6-oxo-17-(2-phenylethyl)morphinanium-iodide.